Pfizer signs $1.25bn cancer antibody licensing deal with China’s 3SBio

Pfizer has entered into an exclusive global, ex-China, licensing agreement with 3SBio a Chinese biopharmaceutical company, listed on the Hong Kong Stock Exchange (HKEX), according to a May 19 company announcement. 

¬ Haymarket Media Limited. All rights reserved.